As I can tell from his post, Doc328 was not advertising the wonderful working of Belsomra.
He/she was merely pointing out what incredible hurdles a big pharma must take to submit a successful submission with the FDA for a drug approval for Alzheimer related sleep disturbances(64 patient study measured sleep with polysomnogram and also measured CGI-S and a caregiver-reported participant subjective Sleep Quality Rating), let alone a small biotech....
Xena it never fails, throughout history often times the drug that ultimately gets approved has serious side effects that are many times worse than the original disease or in this case insomnia.....BUT IT GETS APPROVED ANYWAY! I pray that for the 21 or 23 phase 2a patients and for the new hundreds of patients that the side effects are minimal once titration gets them to their “optimized” dose. Slight dizziness is a far cry from lethargy or the inability to move during sleep!